As of September 2026, “peptide” has no single legal status: an offer may involve an FDA-approved drug, a lawfully compounded medicine or an unapproved drug.
Claim source: FDA compounding and drug-approval material, summarized in CA-lanes-01.
Pin down “peptide therapy”
Start with the question that is holding up your decision. Each answer points to the longer page when more detail matters.
Question one
Peptides are real substances, small strings of the units proteins are made from, and some are real medicines. The phrase “peptide therapy” is too broad to tell you which medicine, product or care route is involved. Ask for the exact generic name.
Question two
The answer depends on three things: the exact product, the person prescribing it and the pharmacy that makes or fills it. Change any one and the rules can change.
As of September 2026, “peptide” has no single legal status: an offer may involve an FDA-approved drug, a lawfully compounded medicine or an unapproved drug.
Claim source: FDA compounding and drug-approval material, summarized in CA-lanes-01.
Do not accept “peptides are always allowed” or “peptides are always banned” as a complete answer. Both skip the details that decide the issue.
Question three
As of September 2026, Colorado board policy allows a new clinician-patient relationship to begin online when normal care standards are met, but a prescription that rests on an online questionnaire alone is not acceptable.
Claim source: Colorado Medical Board Policies 40-03 and 40-27, summarized in GEO-CO-12 and GEO-CO-13.
In a careful online visit, the clinician asks follow-up questions, goes over your health history and is free to say no to treatment. A checkout flow with no real exchange is different.
Question four
No. It means made to order rather than sold as an approved finished product. The key distinction is that the finished compounded medicine did not go through FDA approval.
Every compounded medicine is unapproved by the FDA, even when a properly licensed pharmacy made it for a valid patient need.
Claim source: FDA risks of compounded drugs, summarized in CA-compounding-02.
Question five